A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD

SRX246 - Azevan

https://www.abstractsonline.com/pp8/#!/10485/presentation/14634

J. DIFEDE1; L. SPIELMAN2; A. MCALEAVEY1; M. EMERICH1; K. WYKA1; J. KOCSIS1; M. OLDEN1; A. JICK1; J. GORDON-ELIOT1; D. ITZKOWITZ3; S.-F. LU4,5; E. DAMIANO3; M. BROWNSTEIN3; N. SIMON4,3

Dec 20, 2021